PPT-Therapeutics for Hemophilia A

June 2013 Roger L Lundblad PhD Consultant in Biotechnology Chapel Hill North Carolina httpwwwlundbladbiotechcom And Adjunct Professor Department of Pathology University of North Carolina Chapel Hill North Carolina. Nairobi, Kenya. June 24, 2013. Jim Munn, R.N., M.S.. Program Nurse Coordinator. University of Michigan HTC. Ann Arbor, MI, USA. Chair – WFH Nursing . Committee. Acknowledgement. : . Slides 20,21, 23-28 . Soma . Mukherjee. SMU,Chemistry. 5. th. April’2011. Introduction : Protein & important structural features for therapeutics.. Development. Classification. Examples of Protein as targeted delivery device. (. H. aemophilia). By: Morgan Dirienzo. The Royal Disease. Alternate Names and Symptoms. Some alternate names for Hemophilia would be Haemorrhaphilia, or Von Willebrand disease. . The Symptoms for Hemophilia are…. More Than Factor Replacement Prescription. IDG. . Ugrasena. Hematology-oncology division . Child Health . Departement. of Dr. . Soetomo. Hospital - Faculty of Medicine . Airlangga. University. Gen D. Sex-linked inheritance; almost all patients male. Female carriers may have mild symptoms. Most bleeding into joints, muscles; mucosal and CNS bleeding uncommon. Severity inversely proportional to factor level. 1 MGTA - 145, in Combination with Plerixafor, Rapidly Mobilizes Large Numbers of HSCs in Humans That Can Be Gene Edited with CRISPR/Cas9 and Mediate Superior Engraftment to Standard - of - Care Kev WVNHF. Amber Tichnell, Executive Director. Hemophilia and other bleeding disorders. The human body is made up of several clotting factors – Factors 1 through 13 plus Von . Willebrand. Factor. A person can have deficiencies in any of these factors. Hemophilia A. Also known as Factor VIII Deficiency is the most common type of hemophilia. It is a disorder of your blood-clotting system. Clotting is the process which your blood changes from a liquid to a solid state. Andrew J. . Costandi. , MD, MMM . Children’s Hospital Los Angeles. USC Keck School of Medicine. Faculty Disclosures. None. Learning Objectives. Upon completion of this activity, participants will be able to:. . Chelsea Marion, MD. 1,4. , Oluwaseun Odewole, MD, MPH. 2,4. , Sheila Goel, MD. 3,4. . 1. Dept. of Pediatrics, Morehouse School of Medicine, Atlanta, GA. . 2. Dept. of Family Medicine, Morehouse School of Medicine, Atlanta, GA. . Mukherjee. SMU,Chemistry. 5. th. April’2011. Introduction : Protein & important structural features for therapeutics.. Development. Classification. Examples of Protein as targeted delivery device. Robin Reid, MD. Clinical Director, Mary M Gooley Hemophilia Center. Hematologist and Medical Oncologist, Rochester Regional Health. July . 2021. Outline. History of the Mary M Gooley Hemophilia Treatment Center. Lizheng Shi, PhD, . MsPharm. Regents Professor and Interim Chair. Department of Health policy and Management. School of Public Health and Tropical Medicine. Funded by BioMarin Pharmaceutical, which provided input into study design.. Alfonso Iorio, MD PhD. McMaster University, Canada. Alfonso Iorio. MD, PhD, FRCPC. Professor of Medicine. McMaster University. Disclosures. McMaster University has received research, consultancy and educational funding for Population PK projects from Bayer, .